BioCentury | May 17, 2010
Company News

ChronTech, Kringle deal

...its ownership and subsequent revenue sharing in the partners' ChronSeal wound healing program. ChronTech (formerly Tripep AB...
BioCentury | Dec 14, 2009
Clinical News

ChronVac-C: Phase I/II ongoing

...enrolled in the dose-escalation, Swedish Phase I/II trial received 4 vaccinations of ChronVac-C given monthly. Tripep...
...vaccine is delivered using Inovio's Medpulser electroporation platform. Inovio Biomedical Corp. (NYSE-A:INO), San Diego, Calif. Tripep AB...
BioCentury | Dec 7, 2009
Financial News

Tripep proposes rights offering

Tripep AB (SSE:TPEP), Huddinge, Sweden Business: Infectious Date announced: 11/27/09 Type: Rights offering To be raised: Up to SEK17.8 million ($2.6 million) Shares: 35.6 million Price: SEK0.50 Shares outstanding prior: 35.6 million Investors: Existing investors...
BioCentury | Dec 7, 2009
Clinical News

ChronVac-C: Phase I/II data

...BioCentury, July 7, 2008 & Nov. 17, 2008). Inovio Biomedical Corp. (NYSE-A:INO), San Diego, Calif. Tripep AB...
BioCentury | Aug 31, 2009
Company News

Cosmix molecular biologicals GmbH, Opsonic, Tripep deal

...Newco Opsonic received exclusive, worldwide licenses to Tripep's redirecting antibody specificity ( RAS ) technology and...
...library technology to identify target-binding peptides to treat autoimmune, cancer and infectious diseases. Cosmix and Tripep...
...in Opsonic. Cosmix molecular biologicals GmbH , Braunschweig, Germany Opsonic Therapeutics Inc. , Marlborough, Mass. Tripep AB...
BioCentury | Aug 10, 2009
Financial News

Tripep completes private placement

...$139,000) Shares: 2 million Price: SEK0.50 Shares after offering: 35.6 million Investors: Existing investors Note: Tripep...
BioCentury | Jul 27, 2009
Financial News

Tripep completes private placement

Tripep AB (SSE:TPEP), Huddinge, Sweden Business: Infectious Date completed: 7/21/09 Type: Private placement Raised: SEK2 million ($258,600) Shares: 4 million Price: SEK0.50 Shares after offering: 33.6 million Investors: Existing investors WIR Staff Infectious...
BioCentury | Jul 13, 2009
Financial News

Tripep completes private placement

Tripep AB (SSE:TPEP), Huddinge, Sweden Business: Infectious Date completed: 7/7/09 Type: Private placement Raised: SEK3 million ($383,700) Shares: 6 million Price: SEK0.50 Shares after offering: 29.6 million Investors: New investors; existing investors WIR Staff Infectious...
BioCentury | May 4, 2009
Company News

Kringle, Maruho deal

...disclosed. The companies signed a letter of intent for the right in February. Kringle and Tripep AB...
BioCentury | Apr 6, 2009
Company News

Tripep management update

Tripep AB (SSE:TPEP), Huddinge, Sweden Business: Infectious Departing: Jan Nilsson as CEO; Anders Vahlne, head of R&D, will serve as acting CEO WIR Staff Infectious...
Items per page:
1 - 10 of 75
BioCentury | May 17, 2010
Company News

ChronTech, Kringle deal

...its ownership and subsequent revenue sharing in the partners' ChronSeal wound healing program. ChronTech (formerly Tripep AB...
BioCentury | Dec 14, 2009
Clinical News

ChronVac-C: Phase I/II ongoing

...enrolled in the dose-escalation, Swedish Phase I/II trial received 4 vaccinations of ChronVac-C given monthly. Tripep...
...vaccine is delivered using Inovio's Medpulser electroporation platform. Inovio Biomedical Corp. (NYSE-A:INO), San Diego, Calif. Tripep AB...
BioCentury | Dec 7, 2009
Financial News

Tripep proposes rights offering

Tripep AB (SSE:TPEP), Huddinge, Sweden Business: Infectious Date announced: 11/27/09 Type: Rights offering To be raised: Up to SEK17.8 million ($2.6 million) Shares: 35.6 million Price: SEK0.50 Shares outstanding prior: 35.6 million Investors: Existing investors...
BioCentury | Dec 7, 2009
Clinical News

ChronVac-C: Phase I/II data

...BioCentury, July 7, 2008 & Nov. 17, 2008). Inovio Biomedical Corp. (NYSE-A:INO), San Diego, Calif. Tripep AB...
BioCentury | Aug 31, 2009
Company News

Cosmix molecular biologicals GmbH, Opsonic, Tripep deal

...Newco Opsonic received exclusive, worldwide licenses to Tripep's redirecting antibody specificity ( RAS ) technology and...
...library technology to identify target-binding peptides to treat autoimmune, cancer and infectious diseases. Cosmix and Tripep...
...in Opsonic. Cosmix molecular biologicals GmbH , Braunschweig, Germany Opsonic Therapeutics Inc. , Marlborough, Mass. Tripep AB...
BioCentury | Aug 10, 2009
Financial News

Tripep completes private placement

...$139,000) Shares: 2 million Price: SEK0.50 Shares after offering: 35.6 million Investors: Existing investors Note: Tripep...
BioCentury | Jul 27, 2009
Financial News

Tripep completes private placement

Tripep AB (SSE:TPEP), Huddinge, Sweden Business: Infectious Date completed: 7/21/09 Type: Private placement Raised: SEK2 million ($258,600) Shares: 4 million Price: SEK0.50 Shares after offering: 33.6 million Investors: Existing investors WIR Staff Infectious...
BioCentury | Jul 13, 2009
Financial News

Tripep completes private placement

Tripep AB (SSE:TPEP), Huddinge, Sweden Business: Infectious Date completed: 7/7/09 Type: Private placement Raised: SEK3 million ($383,700) Shares: 6 million Price: SEK0.50 Shares after offering: 29.6 million Investors: New investors; existing investors WIR Staff Infectious...
BioCentury | May 4, 2009
Company News

Kringle, Maruho deal

...disclosed. The companies signed a letter of intent for the right in February. Kringle and Tripep AB...
BioCentury | Apr 6, 2009
Company News

Tripep management update

Tripep AB (SSE:TPEP), Huddinge, Sweden Business: Infectious Departing: Jan Nilsson as CEO; Anders Vahlne, head of R&D, will serve as acting CEO WIR Staff Infectious...
Items per page:
1 - 10 of 75